

ESPI current report

Number: 42/2025
Date of preparation: December 11, 2025
Company: Genomtec SA

Title	Receipt of a decision from the United States Patent Office to grant patent protection.
--------------	---

Legal basis: Article 17 paragraph 1 of MAR - confidential information.

Content of the Report: The Management Board of Genomtec S.A. with its registered office in Wrocław (the "Issuer", "Company") hereby announces that on December 11, 2025, it received information that the United States Patent Office issued a decision to grant a patent for the invention entitled "Primer sets for the detection of human papillomavirus type 16 (HPV16) and human papillomavirus type 18 (HPV18), the method of detecting HPV16 and HPV18 infections, the use of a primer set for the detection of HPV16 and HPV18 infections", used to detect HPV16 and HPV18 viruses.

HPV16 and HPV18 are sexually transmitted viruses belonging to the human papillomavirus family. Due to their oncogenic properties, they are one of the main causes of cervical cancer development. Early diagnosis of HPV infection allows for the rapid initiation of appropriate therapeutic and diagnostic procedures and further monitoring of the patient to reduce the risk of cancer development, or for rapid diagnosis and further treatment.

The term of protection for the invention in question was granted by the United States Patent Office for a period of up to 20 years, provided that the official fee is paid on time.

The Issuer announces that this is the fourth patent granted by the United States Patent and Trademark Office and the nineteenth patent received by the Company. The Issuer has over thirty patent applications pending worldwide.

In the opinion of the Management Board, a high level of intellectual property protection will also provide the Company with an appropriate negotiating position before signing commercial agreements with selected partners regarding the implementation of the commercialization strategy.

Patent proceedings are aimed at securing key interests and are consistent with the Issuer's development strategy, which includes building a portfolio of intellectual property rights.

Signatures of persons representing the Company:

Michał Wachowski - Member of the Management Board

